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ABSTRACT
Introduction: Clerodendron infortunatum Linn. 
(Verbenaceae), commonly known as Bhant in Hindi, 
is a small shrub occurring throughout the plains 
of India, which is traditionally used for several 
medicinal purposes. The aim of the present study 
was to evaluate the preclinical antihyperglycemic 
activity of the methanol extract of the leaves of 
C. infortunatum (MECI) in Wistar rats. Methods:
Hyperglycemia was induced in rats by a single 
intraperitoneal injection of streptozotocin (STZ, 
65 mg/kg body weight). Three days after STZ 
induction, the hyperglycemic rats were treated 
with MECI intraperitoneally at the doses of 250 
and 500 mg/kg body weight daily for 15 days. 
Glibenclamide (0.5 mg/kg, orally) was used as a 
reference drug. The fasting blood glucose levels 
were measured on every fifth day during the 15 days 
of treatment. Serum biochemical parameters such 
as glutamate pyruvate transaminase, glutamate 
oxaloacetate transaminase, alkaline phosphatase, 
cholesterol, and total protein were estimated. 
Antioxidant properties were assessed by estimating 
hepatic lipid peroxidation, reduced glutathione 
(GSH), and catalase (CAT). Results: MECI at the 
doses of 250 and 500 mg/kg intraperitoneally 
significantly (P<0.001) and dose-dependently 
reduced and normalized blood glucose levels 
as compared to that of the STZ control group. 
Serum biochemical parameters were significantly 
(P<0.001) restored towards normal levels in MECI-
treated rats as compared to the STZ control. MECI 
treatment also significantly (P<0.001) decreased 
lipid peroxidation and recovered GSH levels and 
CAT activity towards normal values, as compared 
to the STZ control. Conclusion: The present study 
demonstrated that the leaves of C. infortunatum
had remarkable preclinical antihyperglycemic 
activity in STZ-induced diabetic rats.
Keywords:  antihyperglycemic; antioxidant; 
Clerodendron infortunatum; glibenclamide; 
streptozotocinDiabetes Ther (2011)  2(2):92-100. 93
INTRODUCTION
Diabetes mellitus is a chronic metabolic disorder 
of carbohydrate, lipid, and protein metabolism. 
It is characterized by hyperglycemia, glycosurea, 
hyperlipidemia, negative nitrogen balance, 
and sometimes ketonemia, due to insufficient 
or complete cessation of insulin synthesis, or 
secretion and/or peripheral resistance to insulin 
action. Diabetes is still not completely curable by 
current antidiabetic drugs. Insulin therapy is the 
only satisfactory approach in diabetes mellitus, 
even though it has several drawbacks, such as 
insulin resistance, anorexia, brain atrophy, and 
fatty liver, in chronic treatment.1 Treatment 
of patients with type 2 diabetes mellitus with 
oral hypoglycemic agents like sulfonylureas 
and biguanides, is always associated with side 
effects.2 Therefore, herbal drugs are gaining 
popularity in the treatment of diabetes mellitus. 
The main benefits of herbal medicine seem to be 
their efficacy, low incidence of adverse effects, 
and low cost.
Clerodendron infortunatum Linn. 
(Verbenaceae), commonly known as Bhant in 
Hindi, is a small shrub occurring throughout 
the plains of India. This plant has been used 
in Indian folk medicine in the treatment of 
bronchitis, asthma, fever, burning sensation, 
diseases of the blood, inflammation, and 
epilepsy.3,4 Traditionally, the plant is used as an 
antipyretic and anthelmintic. Leaves of the plant 
are prescribed for tumors, certain skin diseases, 
and scorpion stings.5 Previous phytochemical 
investigation of the plant revealed the presence 
of alkyl sterols and 2,-(3,4-dehydroxyphenyl) 
ethanol 1-O-α-2 rhamnopyranosyl-(1→3)-β-D-
(4-O-caffeoyl) glycopyranoside or acteoside.6,7 
Previous work has reported hepatoprotective, 
anti-inflammatory, antinociceptive, and 
neuropharmacological activities of C. 
infortunatum.8-10 Until now, there have been no 
reports on antidiabetic investigations of this 
plant. The present study was therefore intended 
to investigate the preclinical antihyperglycemic 
effect of the methanol extract of the leaves of 
C. infortunatum (MECI) against streptozotocin 
(STZ)-induced diabetic Wistar rats.
MATERIALS AND METHODS
Plant Material
The leaves of C. infortunatum were collected 
in November 2008 from the forest region of 
Midnapore state, West Bengal, India. The plant 
species was authenticated at the Central National 
Herbarium, Botanical Survey of India, Howrah, 
West Bengal, India. The voucher specimen (no. 
PMU-4/JU/2008) has been preserved in the 
Pharmacology Research Laboratory, Jadavpur 
University, Kolkata, India for future reference. 
The leaves were dried under shade and then 
powdered using a mechanical grinder into a 
coarse powder.
Preparation of Extract
The powdered plant material was extracted 
with 80% methanol using Soxhlet extraction 
apparatus. The solvent was removed completely 
under reduced pressure and a semisolid mass was 
obtained (MECI, yield 13.5% w/w). The extracts 
were stored in a vacuum desiccator for further 
use. Preliminary phytochemical screening of 
the MECI plant extract showed the presence of 
flavonoids, tannins, and saponins. 
Animals 
Adult male Wistar albino rats weighing 170-200 g 
were used for the present investigation. They 
were housed in a clean polypropylene cage and 
maintained under standard laboratory conditions 94 Diabetes Ther (2011)  2(2):92-100.
(temperature 25±2°C with dark/light cycle 
12/12 h). They were fed a standard pellet diet 
(Hindustan Lever, Kolkata, India) and received 
water ad libitum. The animals were acclimatized 
to laboratory conditions for 1 week prior to 
the experiment. All experimental procedures 
described were reviewed and approved by the 
University Animal Ethics Committee, Jadavpur 
University.
Drugs and Chemicals
STZ, 5,5-dithio bis-2-nitro benzoic acid, reduced 
glutathione (GSH), and nitroblue tetrazolium 
were obtained from SISCO Research Lab, Mumbai, 
India; thiobarbituric acid and trichloroacetic 
acid were obtained from Merck, Mumbai, 
India; potassium dichromate and glacial acetic 
acid were obtained from Ranbaxy, Mumbai; 
glibenclamide was obtained from Hoechst, India. 
All other reagents used were of analytical grade 
and were obtained commercially.
Induction of Diabetes
Diabetes mellitus was induced in overnight-
fasted rats by a single intraperitoneal (i.p.) 
injection of STZ (65 mg/kg body weight [b.w.]).11
After 3 days, fasting blood glucose levels were 
measured and the animals showing blood 
glucose levels ≥225 mg/dL were used for the 
present investigation.12
Treatment Schedule and Estimation of 
Fasting Blood Glucose Level
The rats were divided into five groups (n=6). 
Except for group I, which served as normal 
nondiabetic controls, all other groups consisted 
of diabetic rats. Group I received normal saline 
(5 mL/kg b.w.). Group II served as diabetic (STZ) 
controls. Groups III and IV received MECI (250 
and 500 mg/kg b.w., i.p., respectively), and group 
V received the reference drug, glibenclamide 
(0.5 mg/kg b.w., orally), daily for 15 days. Fasting 
blood glucose was measured on the days 0, 5, 
10, and 15 using a one-touch glucometer (Accu-
check) and the body weights of rats from each 
group were measured both before and 15 days 
after treatment. Twenty-four hours after the last 
dose, blood was collected from overnight-fasted 
rats from each group by cardiac puncture in 
order to estimate serum biochemical parameters. 
The rats were then killed by cervical dislocation 
for the study of liver biochemical parameters.13
Estimation of Serum Biochemical Parameters
Collected blood was used for the estimation 
of serum biochemical parameters viz. serum 
glutamate oxaloacetate transaminase (SGOT), 
serum glutamate pyruvate transaminase (SGPT), 
serum alkaline phosphatase (SALP), serum 
cholesterol, and total protein contents by 
using commercially available reagent kits (Span 
Diagnostics, Surat, India).
Estimation of Liver Biochemical Parameters
Lipid peroxidation, ie, thiobarbituric acid reactive 
substances (TBARS), was estimated by a previously 
reported method and expressed as millimoles 
per 100 g of tissue.14 GSH was determined by a 
previously reported method and was expressed 
as milligrams per 100 g of tissue.15 Catalase (CAT) 
activity was assayed according to the method 
described earlier, and expressed as micromoles of 
hydrogen peroxide (H2O2) consumed per minute 
per milligram of liver tissue.16
Statistical Analysis
The experimental results were expressed as 
mean ± standard error of mean (SEM). Statistical Diabetes Ther (2011)  2(2):92-100. 95
significance was analyzed by one-way analysis 
of variance, followed by Dunnett’s test using 
computerized Graph Pad InStat version 3.05, 
Graph pad software, USA. P values of <0.001 
were considered to be statistically significant.
RESULTS
Fasting Blood Glucose 
The fasting blood glucose levels of normal, 
diabetic, and treated rats are summarized in 
Table 1. STZ at the dose of 65 mg/kg produced 
marked hyperglycemia as evident from a 
significant (P<0.001) elevation in fasting 
blood glucose level in the STZ control group 
as compared to the normal control group. 
Administration of MECI in STZ-induced diabetic 
rats at the doses of 250 and 500 mg/kg b.w. 
produced a significant (P<0.001) and dose-
dependent decrease in blood glucose levels when 
compared with the STZ control group.
Body Weight
The body weight of rats from the STZ control 
group (after 15 days) was significantly (P<0.001) 
decreased when compared with the normal 
control group. MECI at 250 and 500 mg/kg b.w. 
significantly (P<0.001) increased body weight 
towards normal levels in a dose-dependent 
manner compared to the STZ control group 
(Table 2).
Serum Biochemical Parameters
Biochemical parameters such as SGOT, SGPT, 
SALP, and serum cholesterol in the STZ control 
group were significantly (P<0.001) elevated 
as compared to the normal control group. 
Treatment with MECI at the doses of 250 and 
500 mg/kg b.w. significantly (P<0.001) changed 
the SGOT, SGPT, SALP, and serum cholesterol 
levels towards the normal values in a dose-
dependent manner. The total protein was found 
to be significantly decreased in the STZ control 
group as compared with the normal control 
group (P<0.001). Administration of MECI in 
diabetic animals significantly (P<0.001) increased 
the total protein content as compared with the 
STZ control group (Table 3).
Liver Biochemical Parameters
The levels of TBARS were significantly (P<0.001) 
increased in STZ control animals as compared to 
Table 1. Effect of the methanol extract of the leaves of Clerodendron infortunatum (MECI) on fasting blood glucose levels in 
hyperglycemic rats.
    Fasting blood glucose level (mg/dL)
Group  Dose  Day 0  Day 5  Day 10  Day 15
I (Normal control)  5 mL/kg  75.22±3.2  74.32±2.3  76.81±3.5  78.40±1.7
II (STZ)  65 mg/kg  261.54±10.2*  275.35±9.8*  283.21±12.62*  296.72±10.6*
III (STZ+MECI)  250 mg/kg  258.23±10.7  145.58±8.6†  112.45±2.4†  96.42±2.5†
IV (STZ+MECI)  500 mg/kg   260.76±6.4  97.37±3.4†  86.22±2.1†  75.52±3.8†
V (STZ+Gliben)  0.5 mg/kg  266.33±7.3  95.96±6.8†  84.33±3.4†  74.56±3.5†
Values are expressed as mean ± standard error of the mean (n=6).
*P<0.001 compared with normal control.
†P<0.001 compared with STZ control.
Gliben=glibenclamide; STZ=streptozotocin.96 Diabetes Ther (2011)  2(2):92-100.
the normal control group. Treatment with MECI 
at 250 and 500 mg/kg b.w. significantly (P<0.001) 
reduced the TBARS levels when compared with 
STZ control animals in a dose-related manner. The 
level of GSH was significantly (P<0.001) depleted 
in the STZ control group as compared with the 
normal control group. Reduced GSH levels were 
found to be significantly and dose-dependently 
(P<0.001) elevated towards normal levels on 
administration of MECI, as compared with the STZ 
control group. There was a significant (P<0.001) 
reduction in CAT activity in the STZ control group 
compared with the normal group. Administration 
of MECI significantly (P<0.001) recovered CAT 
activity towards normal levels when compared 
with STZ control animals (Table 4).
DISCUSSION
The present work was intended to study 
the antihyperglycemic activity of MECI in 
STZ-induced diabetic rats. The results of this 
study revealed that MECI at doses of 250 and 
500 mg/kg b.w. significantly normalized elevated 
blood glucose levels and restored serum and liver 
biochemical parameters towards normal values. 
Table 2. Effect of the methanol extract of the leaves of Clerodendron infortunatum (MECI) on the body weight of 
hyperglycemic rats.
    Initial body weight   Final body weight
Group  Dose  (g)  (g)
I (Normal control)  5 mL/kg  175.46±1.6  178.36±4.6
II (STZ)  65 mg/kg  172.52±2.6  148.21±2.3*
III (STZ+MECI)  250 mg/kg   170.23±2.8  154.61±2.5†
IV (STZ+MECI)  500 mg/kg   174.32±1.2  151.62±1.2†
V (STZ+Gliben)  0.5 mg/kg  171.25±3.8  159.76±2.8†
Values are expressed as mean ± standard error of the mean (n=6).
*P<0.001 compared with normal control.
†P<0.001 compared with STZ control group.
Gliben=glibenclamide; STZ=streptozotocin.
Table 3. Effect of the methanol extract of the leaves of Clerodendron infortunatum (MECI) on serum biochemical 
parameters in hyperglycemic rats.
        Total    Serum 
    SGOT  SGPT  serum protein  SALP  cholesterol 
Group  Dose  (IU/L)  (IU/L)  (g/dL)  (U/L)  (mg/dL)
I(Normal control)  5 mL/kg  20.24±5.6  23.62±4.7  6.52±2.6  171.22±12.0  155.76±8.4
II (STZ)  65 mg/kg  36.5± 4.2*  39.41±5.2*  3.41±1.7*  243.5±12.5*  224.5±12.4*
III (STZ+MECI)  250 mg/kg   28.9±3.4†  29.5±3.4†  5.78±2.8†  206.56±11.2†  182.8±11.2†
IV (STZ+MECI)  500 mg/kg  22.5±3.5†  24.62±3.5†  6.60±3.8†  177.6±14.9†  159.54±10.3†
V (STZ+Gliben.)  0.5 mg/kg  22.34±2.4†  25.32±3.6†  6.23±3.45†  174.82±10.6†  162.21±11.2†
Values are expressed as mean ± standard error of the mean (n=6).
*P<0.001 compared with normal control.
†P<0.001 compared with STZ control group. 
Gliben=glibenclamide; SALP=serum alkaline phosphatase; SGOT=serum glutamate oxaloacetate transaminase; 
SGPT= serum glutamate pyruvate transaminase; STZ=streptozotocin.Diabetes Ther (2011)  2(2):92-100. 97
STZ is an antibiotic obtained from Streptomyces 
achromogenes. It possesses diabetogenic properties 
mediated by pancreatic β-cell destruction, hence 
this compound has been widely used to induce 
diabetes mellitus in experimental animals.17 
Once STZ enters cells, it undergoes spontaneous 
decomposition to form an isocyanate and a 
methyldiazohydroxide compound. The isocyanate 
and the methyldiazohydroxide compound cause 
intramolecular carboxylation and alkylation, 
respectively, of cellular components.18 The DNA 
damage to the pancreatic β cells is mainly caused 
by alkylation with carbonium ions produced by 
the methyldiazohydroxide compound.19 STZ is 
not only damaging to the pancreatic β cells, but 
it is also harmful to hepatocytes, nephrons, and 
cardiomyocytes.20
Hyperglycemia was observed after 3 days 
of STZ induction in the present study. Dose-
dependent treatment with MECI in STZ-
induced diabetic rats started to reduce fasting 
blood glucose levels after 5 days, leading 
to normoglycemic levels after 15 days. The 
antihyperglycemic effect of MECI at the 500 mg/
kg b.w. dose was found to be more effective and 
comparable to the effect exerted by the reference 
drug, glibenclamide, at the dose of 0.5 mg/kg b.w. 
MECI also showed a marked effect in controlling 
the loss of body weight in diabetic rats.
Elevation of serum hepatic biomarker enzymes, 
such as SGOT, SGPT, and SALP, was observed in 
diabetic rats, indicating impaired liver function, 
which may be due to hepatic damage. The 
decreased total protein content in STZ-induced 
animals also substantiated the hepatic damage 
caused by STZ. Diabetic complications, such 
as increased gluconeogenesis and ketogenesis, 
may be due to elevated transaminase activities.21 
Fifteen days of treatment with MECI restored all 
the abovementioned parameters towards normal 
levels in a dose-dependent manner. It is well 
known that in uncontrolled diabetes mellitus 
there is an increase in total cholesterol present in 
blood, which may contribute to coronary artery 
diseases.22 In the present study, the elevated 
serum cholesterol levels in diabetic rats was 
normalized after treatment with MECI. This 
suggests that the extract may inhibit the pathway 
of cholesterol synthesis in diabetic rats. 
Oxidative stress in diabetes mellitus has 
been shown to coexist with a reduction in the 
endogenous antioxidant status.23 Several sources 
Table 4. Effect of methanol extract of Clerodendron infortunatum leaf (MECI) on liver biochemical parameters in 
hyperglycemic rats.
       CAT  
    TBARS  GSH  (µmol H2O2 
    (mM/100 g  (mg/100 g  consumed/min/mg 
Group  Dose  wet liver tissue)  wet liver tissue)  wet liver tissue)
I (Normal control)  5 mL/kg  1.16±0.4  43.32±1.5  82.18±3.5
II (STZ)  60 mg/kg  2.05±0.3*  24.16±1.4*  45.38±4.1*
III (STZ+MECI)  250 mg/kg   1.32±0.41†  35.21±1.2†  68.39±5.6†
IV (STZ+MECI)  500 mg/kg   1.18±0.52†  40.12±1.1†  78.42±3.8†
V (STZ+Gliben)  0.5 mg/kg  1.17±0.41†  41.08±1.2†  80.49±4.8†
Values are expressed as mean ± standard error of the mean (n=6).
*P<0.001 compared with normal control.
†P<0.001 compared with STZ control group.
CAT=catalase; Gliben=glibenclamide; GSH=reduced glutathione; TBARS=thiobarbituric acid reactive substances; 
STZ=streptozotocin.98 Diabetes Ther (2011)  2(2):92-100.
of evidence suggest that STZ induces oxidative 
stress.17 Oxidative stress is caused by a relative 
overproduction of reactive oxygen species 
(ROS). ROS results in lipid peroxidation and, 
subsequently, increased TBARS levels, leading 
to degradation of cellular macromolecules. A 
marked increase in the concentration of hepatic 
TBARS in STZ-induced diabetic rats indicates 
enhanced lipid peroxidation, leading to tissue 
injury and failure of the antioxidant defense 
mechanisms to prevent overproduction of 
ROS. Lipid peroxidation is usually measured 
in terms of TBARS as a biomarker of oxidative 
stress.24 Treatment with META-inhibited hepatic 
lipid peroxidation in diabetic rats, as revealed 
by a reduction in TBARS levels towards normal 
values. This indicates the inhibition of free-
radical generation in STZ-induced diabetic rats.
GSH plays an important role in the 
endogenous nonenzymatic antioxidant system. It 
acts primarily as a reducing agent and detoxifies 
hydrogen peroxide in the presence of an enzyme, 
glutathione peroxidase.25 The depleted GSH levels 
may be due to a reduction in GSH synthesis 
or degradation of GSH by oxidative stress in 
STZ-induced hyperglycemic animals.26 MECI 
treatment significantly elevated the depleted 
hepatic GSH levels towards normal values in 
diabetic rats. The results of the present study 
showed that the antihyperglycemic activity of 
MECI was accompanied by an enhancement 
in nonenzymatic antioxidant protection. 
These findings suggest that MECI may exert 
its antihyperglycemic effect through the 
enhancement of the cellular antioxidant system. 
Enzymatic antioxidant mechanisms play an 
important role in the elimination of ROS. CAT 
is a heme-containing enzyme catalyzing the 
detoxification of hydrogen peroxide to water and 
oxygen.27 The inhibition of CAT activity as a result 
of STZ-induced hyperglycemia has been reported 
previously, and similar findings were observed 
in the present study.13,28 MECI treatment caused 
a significant recovery of CAT activity towards 
normal levels in a dose-dependent manner.
Diabetes mellitus is generally characterized 
by chronic, low-grade inflammation.29 
Previous studies have confirmed the anti-
inflammatory efficacy of MECI.10 This property 
may be responsible for augmenting the 
antihyperglycemic potential of MECI and 
maintaining normalized parameters.
Preliminary phytochemical studies showed 
the presence of flavonoids, tannins, and saponins 
in MECI. Flavonoids and tannins are well-known 
polyphenolic natural antioxidants, which may be 
responsible for the antioxidant role of MECI.30
CONCLUSION
In the present study, administration of MECI to 
STZ-induced hyperglycemic rats demonstrated 
a prominent reduction in blood glucose levels 
and normalization of serum biochemical profiles 
when compared to STZ control rats. Also, MECI 
treatment resulted in significant modulation of 
lipid peroxidation, endogenous nonenzymatic 
(GSH) and enzymatic (CAT) antioxidant and 
detoxification systems. Therefore, it can be 
concluded that at the preclinical level, the 
methanol extract of the leaves of C. infortunatum is 
remarkably effective against STZ-induced diabetes 
in Wistar rats, plausibly due to its augmenting 
endogenous antioxidant mechanisms. It can be 
further inferred that C. infortunatum leaves may 
serve as an interesting candidate for the effective 
management of diabetes mellitus.
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